Agilent receives fda approval for mage-a4 ihc 1f9 pharmdx as a diagnostic tool for use with newly approved tcr t-cell therapy

Santa clara, calif.--(business wire)--agilent technologies inc., (nyse: a) today announced that it has received fda approval for the use of mage-a4 ihc 1f9 pharmdx (sk032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with tecelra® (afamitresgene autoleucel, also known as afami-cel or adp-a2m4), a mage-a4-directed engineered tcr t-cell therapy. mage-a4 (melanoma-associated antigen a4) is a cancer-testis antigen overexpressed in vario.
A Ratings Summary
A Quant Ranking